Post-results note
The next step is becoming clearer - Q2 review
Klas Palin
2026-08-21
08:25 CEST
The financial position has strengthened, extending the cash runway to Q2 2027e, and we expect the ongoing Phase I study to be completed in Q4. The company has initiated preparations for the next stage of development, which we expect to focus on head and neck cancer, initially targeting the rare indication adenoid cystic carcinoma (ACC). Following the Q2 report, we reiterate our fair value of SEK0.22–0.31 per share.
Undramatic numbers. Opex amounted to SEK8.4m in Q2, with operating cash flow at a similar level of SEK-8.3m. We expect opex to increase moderately in H2 as preparations for the next development phase commence. The rights issue completed during the quarter generated net proceeds of SEK14.9m, bringing the end-Q2 cash position to SEK32.5m, which we estimate is sufficient to fund operations to Q2 2027.
Two more patients before Phase I completion. The final two patients scheduled for fractionated dosing in the ongoing Phase I study have yet to be enrolled, but we expect enrolment shortly following recent regulatory clearance. Supported by encouraging results showing visible Tumorad uptake on SPECT/CT imaging in head and neck cancer patients, the company has become increasingly clear that the next stage of development is likely to focus on adenoid cystic carcinoma (ACC) as the initial target indication. ACC is a rare cancer with significant unmet medical need, and we expect further details on the development strategy later this year.
Estimate changes. We make no material changes to our estimates following Q2. The improvement in EPS is purely mechanical, reflecting the increased share count following the recently completed rights issue.
Valuation unchanged. We maintain our fair value of SEK0.22–0.31 per share following the Q2 report. The main near-term event is the completion of the ongoing Phase I study, which we believe would further de-risk the case.